Position in NVS
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$1,926,483
+$289,553 QoQ
Shares Held
12,612
+6.2% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026PCM Encore, LLC holds $23,406,313 across 14 Drug Manufacturers - General names. NVS ranks #4 (8.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
8,857 | $8,146,402 | |
| 2 | ABBV |
AbbVie Inc.
|
10,527 | $2,289,517 | |
| 3 | MRK |
Merck & Co., Inc.
|
17,993 | $2,164,377 | |
| 4 | NVS |
Novartis AG
This page
|
12,612 | $1,926,483 | |
| 5 | JNJ |
Johnson & Johnson
|
7,486 | $1,829,877 | |
| 6 | AZN |
Astrazeneca PLC
|
8,107 | $1,598,862 | |
| 7 | AMGN |
Amgen Inc
|
4,407 | $1,550,602 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
7,278 | $1,014,334 |
All Filings in NVS
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,926,483 | 12,612 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $1,636,930 | 11,873 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||